CancerDrs

Prostate Cancer clinical trials in Missouri

32 actively recruiting prostate cancer trials at 25 sites across Missouri.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • University of Kansas Cancer Center - North — Kansas City, Missouri
  • University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Siteman Cancer Center-South County — St Louis, Missouri
  • Siteman Cancer Center at Christian Hospital — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Southeast Cancer Center — Cape Girardeau, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • University of Missouri - Ellis Fischel — Columbia, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Missouri:
  • Saint Francis Medical Center — Cape Girardeau, Missouri
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • University Health Truman Medical Center — Kansas City, Missouri
  • University of Kansas Cancer Center - Briarcliff — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Missouri:
  • Washington University — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Missouri:
  • Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062) — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Federal

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…

Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Missouri:
  • Kansas City VA Medical Center, Kansas City, MO — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Missouri:
  • Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
  • Central Care Cancer Center - Bolivar — Bolivar, Missouri
  • Parkland Health Center-Bonne Terre — Bonne Terre, Missouri
  • Cox Cancer Center Branson — Branson, Missouri
  • Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in Missouri:
  • Site US10032 — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04071236
Sites in Missouri:
  • Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • University of Kansas Cancer Center at North Kansas City Hospital — North Kansas City, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Siteman Cancer Center-South County — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…

Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in Missouri:
  • Kansas City VA Medical Center, Kansas City, MO — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…

Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Missouri:
  • Kansas City VA Medical Center, Kansas City, MO — Kansas City, Missouri
  • St. Louis VA Medical Center John Cochran Division, St. Louis, MO — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to c…

Sponsor: Convergent Therapeutics
NCT ID: NCT06549465
Sites in Missouri:
  • Washington University in St. Louis — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of A…

Sponsor: AstraZeneca
NCT ID: NCT07336446
Sites in Missouri:
  • Research Site — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as…

Sponsor: David Oh
NCT ID: NCT03821246
Sites in Missouri:
  • Alvin J. Siteman Cancer Center at Washington University — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…

Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…

Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Missouri:
  • Washington University School of Medicine in St. Louis — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive …

Sponsor: Eli Lilly and Company
NCT ID: NCT07114601
Sites in Missouri:
  • Washington University — St Louis, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered…

Sponsor: Exelixis
NCT ID: NCT05932862
Sites in Missouri:
  • Exelixis Clinical Site #10 — Kansas City, Missouri
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regim…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05818683
Sites in Missouri:
  • Washington University School Of Medicine — St Louis, Missouri
View on ClinicalTrials.gov →

Showing 25 of 32 trials with sites in Missouri. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15